BridgeBio Oncology Therapeutics Inc (BBOT)
BridgeBio Oncology Therapeutics Inc is a clinical-stage biotechnology company listed on NASDAQ under the ticker BBOT. The company focuses on developing small-molecule oncology candidates in the United States, with an emphasis on pathways linked to KRAS-related cancers and related precision medicine targets. Its pipeline includes BBO-8520, a Phase I candidate being studied in patients with KRASG12C-mutant non-small cell lung cancer; BBO-11818, a Phase I pan-KRAS inhibitor; and BBO-10203, another Phase I program being evaluated across several cancer settings, including HER2-positive breast cancer, HR-positive/HER2-negative breast cancer, KRAS-mutant colorectal cancer, and KRAS-mutant non-small cell lung cancer. Founded in 2016, the company is headquartered in South San Francisco, California.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-BBOT
|
$5.14
|
7.7% Upside
|
Fair
|
$24.55
|
414.6% Upside
|
Bargain
|
Weak
|
0.0%
|
November 18, 2026
|
1.2x
|
382.4 M
|
40.815 M
|
0.6%
|
44.7%
|
1.6
|
83.2%
|
